/
IBO
$0.50+$0.03 (+6.86%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$50.8M
108M shares
52-week range
$0.37 – $0.83
29% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
XASE
CS
Price (6 mo)
Loading chart…
Change$-2.18
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $1.6M | $32.0K |
| Cost of revenue | $0 | $1.1M | $1.1M | $1.1M | $1.1M | $424.0K |
| Gross profit | $0 | −$1.1M | −$1.1M | −$1.1M | $1.6M | −$392.0K |
| Gross margin | — | — | — | — | 100.0% | -1225.0% |
| R&D | $513.7K | $1.1M | $1.2M | $1.7M | $63.8K | $340.0K |
| Operating income | −$896.7K | −$3.2M | −$3.5M | −$4.0M | $383.4K | −$4.3M |
| EBITDA | −$896.7K | −$2.1M | −$2.3M | −$2.8M | −$1.1M | −$12.5M |
| Net income | −$597.3K | −$1.3M | −$7.1M | −$4.3M | −$1.4M | −$11.8M |
| Net margin | — | — | — | — | -88.0% | -36993.8% |
| EPS (diluted) | -0.05 | -0.61 | -0.61 | -0.07 | -0.01 | -0.38 |
Annual figures · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.00
Price
$0.50
Implied downside
-100%
Peer comparison
Impact BioMedical, Inc.
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir.
www.impactbiomedinc.com- Employees
- 8
- IPO / List date
- Sep 16, 2024
- HQ
- HOUSTON, TX
Held by traders on TradeandTell
No one on the platform currently holds IBO.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in IBO as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded IBO yet.
